Articles from Prolium Bioscience, Inc.

Prolium Bioscience Announces First Patient Dosed in its Multinational, Phase 1/2 Study of PRO-203 in Systemic Sclerosis, and Last Patient, Last Visit in an Investigator-Led Study of PRO-203 in Refractory Lupus Nephritis

Phase 1/2 SSc study is expected to enroll patients at over 20 participating clinical sites in at least five countries

By Prolium Bioscience, Inc. · Via GlobeNewswire · June 22, 2026

Prolium Bioscience Launches with $50 Million and Announces First Patients Dosed with PRO-203, a Potential Best-in-Class CD20xCD3 T-Cell Engager, for Severe Autoimmune Disease

Initial $50M Series A investment from founding investor RTW Investments

By Prolium Bioscience, Inc. · Via GlobeNewswire · March 3, 2026

Articles from Prolium Bioscience, Inc. | MarketMinute